Format

Send to

Choose Destination
Br J Sports Med. 1996 Mar;30(1):36-40.

Effect of low dose oral contraceptives on exercise performance.

Author information

1
Department of Medicine, School of Medicine, West Virginia University, Morgantown 26506-6116, USA.

Abstract

OBJECTIVE:

to examine the effect of cycle phase or a low dose oral contraceptive on exercise performance in young women.

METHODS:

As controls, 15 men were tested twice by a maximal treadmill test (Vo2 max) and by an endurance run 14 d apart to determine performance variability from causes other than hormonal fluctuations. Ten women ages 18-30 were then tested for Vo2 max and endurance in the same way in both the follicular and the luteal phase (random order, ovulation assessed by sonography). They were then randomly assigned to placebo (n = 3) or oral contraceptive (1 mg norethindrone and 35 micrograms ethinyl oestradiol) (n = 7) for 21 days. Tests were repeated during the first and third weeks of treatment. Vo2 max and endurance tests were compared in the men and control cycle of the women by using independent t tests on percent change. The data for both cycles in the women were analysed by repeated measures ANOVA.

RESULTS:

There was no difference in per cent change in total test time, Vo2 max, or breathing frequency between the men and women in either test. Data obtained during the Vo2 max test revealed no difference between the follicular and luteal phases of the menstrual cycle for total test time [11.8 (SD 2.3) v 12.6 (2.3) min], Vo2 [41.6 (12.1) v 39.7 (11.4) ml.kg-1.min-1], or breathing frequency [26.8 (3.5) v 27.3 (9.9) breaths.min-1] respectively, or during the first and third weeks of treatment [total test time 12.0 (2.5) v 12.8 (2.4) min; Vo2 37.3 (7.4) v 41.0 (12.4) ml.kg-1.min-1; breathing frequency 27.8 (4.2) v 27.7 (3.4) breaths.min-1, respectively]. Data obtained during the endurance test revealed no difference between the follicular and luteal phase of the menstrual cycle for total test time [20.5 (15.7) v 16.2 (8.5) min], Vo2 [37.5 (9.4) v 32.9 (8.1) ml.kg-1.min-1], or breathing frequency [32.0 (6.0) v 33.2 (5.1) breaths.min-1, respectively], or during the first and third weeks of treatment [total test time 32.3 (34.9) v 30.6 (30.1) min; Vo2 33.9 (10.1) v 35.2 (8.6) ml.kg-1.min-1; breathing frequency 34.0 (5.9) v 34.8 (5.3) breaths.min-1, respectively].

CONCLUSIONS:

Neither cycle phase nor a low dose oral contraceptive containing 1 mg norethindrone adversely affects performance during a maximal treadmill test or endurance run.

PIP:

The authors examined the effect of cycle phase or a low dose oral contraceptive on the exercise performance of young women. As controls, 15 men were tested twice by a maximal treadmill test and by an endurance run 14 days apart to determine performance variability from causes other than hormonal fluctuations. 10 women aged 18-30 were then tested by maximal treadmill test and endurance in the same manner in both the follicular and luteal phase. They were then randomly assigned to placebo or oral contraceptive for 21 days. Tests were repeated during the first and third weeks of treatment. Maximal treadmill test and endurance tests were compared in the men and control cycle of women using independent t tests on percent change. Neither cycle phase nor a low dose oral contraceptive containing 1 mg norethindrone was found to adversely affect performance during a maximal treadmill test or endurance run.

PMID:
8665116
PMCID:
PMC1332263
DOI:
10.1136/bjsm.30.1.36
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center